Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $42.7 million.

  • Dianthus Therapeutics' Net Cash Flow rose 11522.57% to $42.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 11802.47%. This contributed to the annual value of -$109.4 million for FY2024, which is 19350.5% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' Net Cash Flow stood at $42.7 million, which was up 11522.57% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Net Cash Flow registered a high of $197.4 million during Q1 2024, and its lowest value of -$280.3 million during Q3 2024.
  • For the 4-year period, Dianthus Therapeutics' Net Cash Flow averaged around $3.2 million, with its median value being -$10.9 million (2024).
  • Within the past 5 years, the most significant YoY rise in Dianthus Therapeutics' Net Cash Flow was 241559.83% (2024), while the steepest drop was 33972.14% (2024).
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Net Cash Flow stood at -$21.5 million in 2022, then fell by 15.99% to -$25.0 million in 2023, then skyrocketed by 56.41% to -$10.9 million in 2024, then skyrocketed by 492.38% to $42.7 million in 2025.
  • Its Net Cash Flow was $42.7 million in Q3 2025, compared to $3.1 million in Q2 2025 and -$12.7 million in Q1 2025.